Evolent Health

Aetna Partnership And Demographic Trends Will Redefine Care Delivery

AnalystHighTarget

Not Invested

Consensus Narrative from 13 Analysts

Published

28 Aug 25

AnalystHighTarget's Fair Value

US$20.00

52.1% undervalued

28 Aug

US$9.58

-68.1%

-0.4%

-68.1%

-0.4%

Edit anytime before Aug 28 9:22 PM. Then post Updates to your followers.

Author's Valuation

US$20.0

52.1% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$20.0

52.1% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

12.26%

Healthtech revenue growth rate

4.44%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

9.74%

Calculation

US$46.01m

Earnings '28

67.90x

PE Ratio '28

US$3.12b

Market Cap '28

US$3.12b

Market Cap '28

118.85m

No. shares '28

US$26.29

Share Price '28

US$26.29 Share Price '28

Discounted to 2025 @ 9.81% p.a.

US$19.86

Fair Value '25